1-(indan-2-yl)-4-phenylpiperidine | 269084-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(indan-2-yl)-4-phenylpiperidine
• 英文别名: 1-(2,3-dihydro-1H-inden-2-yl)-4-phenylpiperidine
• CAS: 269084-90-4
• 化学式: C₂₀H₂₃N
• 分子量: 277.409
• InChiKey: QSDVFYICXDIDQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-茚醇 在 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 34.5h， 生成 1-(indan-2-yl)-4-phenylpiperidine
  参考文献：
  名称：

  负的GluN2B NMDA受体的变构调节剂，其苯乙胺结构嵌入环扩展和环收缩的支架中。

  摘要：

  制备了一组具有构象受限的苯乙胺亚结构的GluN2B NMDA受体拮抗剂，并进行了药理学评估。苯乙胺的亚结构包埋在扩环的3-苯甲唑啉4和缩合的四氮杂胺6和茚满胺7中。配体4、6和7是通过仲胺11的还原烷基化，酮12和16的还原胺化以及亲核性合成的Nosylates 14和17的取代。3-benzazocine 4d（Ki = 32 nM）的中等GluN2B亲和力在两电极电压下转化为中等的细胞保护活性（IC50 = 890 nM）和中等的离子通道抑制（10％时为60％）。表达GluN1a / GluN2B的卵母细胞的钳位实验。尽管某些四氢化萘胺6和茚满胺7具有很高的GluN2B亲和力（例如Ki（7f）= 3.2 nM），它们不能抑制谷氨酸/甘氨酸诱导的细胞毒性。3-苯甲唑啉4，四氢萘胺6和茚满胺7的低细胞保护活性归因于苯环和/或苄基位置上缺少的OH部分。对接研究表明，新型GluN2B配体采用与Ro

  DOI：

  10.1016/j.ejmech.2020.112138

文献信息

• Novel compounds
  申请人：SmithKline Beecham SpA

  公开号：US20040024218A1

  公开（公告）日：2004-02-05

  Compounds of formula I, or a salt thereof or a hydrate thereof, as follows: 1 wherein X and Y are selected independently from hydrogen and aryl, which aryl is unsubstituted or substituted one or more times by hydroxy, hydroxyC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, aryl, heterocyclyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkoxy, C 1-6 alkyl, C 1-6 alkoxy or halo, which alkyl or alkoxy groups are unsubstituted or substituted one or more times by halo; m and n are independently 0 to 3, provided that m and n are not both 0; A represents a single bond or is —(CR pa R pb ) p — wherein p is 1-3 and R pa and R pb are selected independently from hydrogen, C 1-6 alkyl, C 1-6 alkoxy and halo, which alkyl or alkoxy groups are independently substituted one or more times by halo; B represents a C 4-8 saturated or unsaturated ring, which ring is unsubstituted or substituted one or more times by C 1-6 alkyl, C 1-6 alkoxy, aryl, aryloxy, hydroxy, oxo, halo, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, and C 1-6 alkylamido, which C 1-6 alkyl or C 1-6 alkoxy groups are unsubstituted or substituted one or more times by halo, which aryl group is unsubstituted or substituted one or more times by aryl, heterocyclyl, aryloxy, arylC 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, arylC 1-6 alkyl, hydroxy, C 1-6 alkenoxy, C 1-6 alkoxy, halo, or C 1-6 alkyl, which C 1-6 alkyl may be substituted one or more times by halo, and which aryl group is linked to said ring by a single bond or is benzo-condensed therewith are ligands of the ORL-1 receptor.

  式I的化合物，或其盐或水合物，如下所示：其中X和Y分别选择自氢和芳基，所述芳基未取代或被羟基、羟基C1-6烷基、C1-6烷氧基C1-6烷基、芳基、杂环烷基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷氧基、C1-6烷基、C1-6烷氧基或卤素取代一次或多次，其中烷基或烷氧基基团未取代或被卤素取代一次或多次；m和n独立地为0到3，但要求m和n不能同时为0；A代表单键或为—(CRpaRpb)p—，其中p为1-3且Rpa和Rpb独立选择自氢、C1-6烷基、C1-6烷氧基和卤素，其中烷基或烷氧基基团独立地被卤素取代一次或多次；B代表C4-8饱和或不饱和环，所述环未取代或被C1-6烷基、C1-6烷氧基、芳基、芳氧基、羟基、氧代、卤素、氨基、C1-6烷基氨基、二(C1-6烷基)氨基和C1-6烷酰胺取代一次或多次，其中C1-6烷基或C1-6烷氧基基团未取代或被卤素取代一次或多次，所述芳基未取代或被芳基、杂环烷基、芳氧基、芳基C1-6烷氧基、氨基、C1-6烷基氨基、二(C1-6烷基)氨基、芳基C1-6烷基、羟基、C1-6烯氧基、C1-6烷氧基、卤素或C1-6烷基取代一次或多次，所述C1-6烷基可能被卤素取代一次或多次，所述芳基通过单键与所述环相连或与之苯并结合的化合物是ORL-1受体的配体。
• N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS
  申请人：Smithkline Beecham S.p.A.

  公开号：EP1129072A2

  公开（公告）日：2001-09-05
• US6969724B2
  申请人：——

  公开号：US6969724B2

  公开（公告）日：2005-11-29
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：SMITHKLINE BEECHAM SPA

  公开号：WO2000027815A2

  公开（公告）日：2000-05-18

  Compounds of formula (I) or a salt thereof or a hydrate thereof, as follows: wherein X and Y are selected independently from hydrogen and aryl, which aryl is unsubstituted or substituted one or more times by hydroxy, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, aryl, heterocyclyl, amino, C1-6alkylamino, di(C1-6alkyl)amino, arylC1-6alkoxy, C1-6alkyl, C1-6alkoxy or halo, which alkyl or alkoxy groups are unsubstituted or substituted one or more times by halo; m and n are independently 0 to 3, provided that m and n are not both 0; A represents a single bond or is -(CRpa Rpb)p- wherein p is 1-3 and Rpa and Rpb are selected independently from hydrogen, C1-6alkyl, C1-6alkoxy and halo, which alkyl or alkoxy groups are independently substituted one or more times by halo; B represents a C4-8 saturated or unsaturated ring, which ring is unsubstituted or substituted one or more times by C1-6alkyl, C1-6alkoxy, aryl, aryloxy, hydroxy, oxo, halo, amino, C1-6alkylamino, di(C1-6alkyl)amino, and C1-6alkylamido, which C1-6alkyl or C1-6alkoxy groups are unsubstituted or substituted one or more times by halo, which aryl group is unsubstituted or substituted one or more times by aryl, heterocyclyl, aryloxy, arylC1-6alkoxy, amino, C1-6alkylamino, di(C1-6alkyl)amino, arylC1-6alkyl, hydroxy, C1-6alkenoxy, C1-6alkoxy, halo, or C1-6, which C1-6alkyl may be substituted one or more times by halo, and which aryl group is linked to said ring by a single bond or is benzo-condensed therewith are ligands of the ORL-1 receptor.
• Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds
  作者：Louisa Temme、Elena Bechthold、Julian A. Schreiber、Sandeep Gawaskar、Dirk Schepmann、Dina Robaa、Wolfgang Sippl、Guiscard Seebohm、Bernhard Wünsch

  DOI：10.1016/j.ejmech.2020.112138

  日期：2020.3

  A set of GluN2B NMDA receptor antagonists with conformationally restricted phenylethylamine substructure was prepared and pharmacologically evaluated. The phenylethylamine substructure was embedded in ring expanded 3-benzazocines 4 as well as ring-contracted tetralinamines 6 and indanamines 7. The ligands 4, 6 and 7 were synthesized by reductive alkylation of secondary amine 11, reductive amination

  制备了一组具有构象受限的苯乙胺亚结构的GluN2B NMDA受体拮抗剂，并进行了药理学评估。苯乙胺的亚结构包埋在扩环的3-苯甲唑啉4和缩合的四氮杂胺6和茚满胺7中。配体4、6和7是通过仲胺11的还原烷基化，酮12和16的还原胺化以及亲核性合成的Nosylates 14和17的取代。3-benzazocine 4d（Ki = 32 nM）的中等GluN2B亲和力在两电极电压下转化为中等的细胞保护活性（IC50 = 890 nM）和中等的离子通道抑制（10％时为60％）。表达GluN1a / GluN2B的卵母细胞的钳位实验。尽管某些四氢化萘胺6和茚满胺7具有很高的GluN2B亲和力（例如Ki（7f）= 3.2 nM），它们不能抑制谷氨酸/甘氨酸诱导的细胞毒性。3-苯甲唑啉4，四氢萘胺6和茚满胺7的低细胞保护活性归因于苯环和/或苄基位置上缺少的OH部分。对接研究表明，新型GluN2B配体采用与Ro